Topical and Systemic Antibiotics
Özet
Antibiotics have been used for many years and areone of the drug groups that have an essential place in treating skin diseases. Topical antibiotics are locally applied forms of antibacterial agents. Advantages over systemic applications include ease of use, low potential for side effects, low risk of incompatibility, low cost and low risk of bacterial resistance. Many diseases coexist in the geriatric patient group, and multiple drug use is seen accordingly. Therefore, the use of topical drugs is safer in elderly patients Indications for use in skin diseases; bacterial infections, wound and burn treatment, acne, rosacea, hidradenitis suppurativa, interventional treatments and eczemas, ulcers, and other secondary infected dermatological diseases. Antibiotics are the most frequently prescribed new drugs in elderly patients. The use of antibiotics in the elderly is of particular importance due to underlying diseases, multiple drug use, drug interactions, and pharmacokinetic and pharmacodynamic changes. Drugs such as digoxin, warfarin, oral hypoglycemics, theophylline, antacids and H2 receptor antag-
onists, lipid-lowering agents, lipophilic β-blocker and non-dihydropyridine calcium channel blockers, which are frequently used by geriatric patients, may interact with antibiotic. Physicians should use rational approaches to prevent antibiotic resistance. They should use drugs for the necessary indication, at the appropriate dose, for a sufficient period, and prevent unnecessary use.
Referanslar
Colebrook, L. (1956). “Alexander Fleming 1881-1955”. Biographical Memoirs of Fellows of the Royal Society. 2: 117–126.
Tunckel AR:Topical antibiotics,pp:428-435.İnMandell G,Bennett JE,Dolin R(Eds),Principlesand Practice of Infectious Diseases 2000, 5th de.Churchill Livingstone, New York.
Erdinçler DS. Yaşlıda İlaç Kullanımı. Sendrom 1998;10:35- 40
Lio PA, Kaye ET. Topical antibacterial agents. Infect Dis Clin North Am. 2009 Dec; 23(4):945-63.
Murphy CS. Clindamycin. Practical Diabetes. 2015 Jul;32 (6): 222-3.
Rist T, Paris LC,Capin LR, Sulice V Bushnell VD,Cupo MA:A comparison of the efficacy and safety of mupirocin cream and cephalexin in thetreatment of secondarily infected eczama. Clindamycin Exp Dermatoloji 2002,27;14-20.
Sutherland R,Boon RJ, Griffin KE,et al:Antibacterial activity of mupirocin a new antibiotic for topical use. Antimicrob Agents Chemother 1985,27:495-498.
Schöfer H, Simonsen L. Fusidic acid in dermatology: An updated review. Eur J Dermatol. 2010;20:6–15.
Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LWA, Morris AD, Butler CC, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012:CD003261. doi: 10.1002
Turnidge J, CollingonP: Resistance to fusidik acid .Int J Antimicrob Agents 1999,12 ( Suppl 2):35-44
Al-Salama ZT, Deeks E. Dapsone 7,5 % gel :A review in anne vulgaris.Am J Clin Dermatol.2017;18:139-45
Augusto BA, Alves PMS. Tetracycline: production, waste treatment and environ- mental impact assessment. Braz. J. Pharm. Sci. [Internet]. 2014 Mar; 50(1):25-40.
Lesher J,Woody MC.Antimikrobiyal ilaçlar . İn:Bolognia JL, Rapini RP,editörs.Dermatoloji( Çevre:Sarıcaoğlu H, Başkan EB),2nd de.İstanbul:Nobel Tıp Kitabevleri:2012.p.1949-952.
Booth JH, Benrimoj SI, Nimmo GR: In vitrro interreactions neomycin sülfat, bacitracin and polymyxin B sulfate. Int J Dermatol 1994, 33:517-520
Yan K, Madden L, Choudhry AE, Voigt CS, Copeland RA, Gontarek Rr. Biochemical charactrrization of the interaction of the Nobel pleuromutilin derivative retapamulin with bacterial ribosomes . Antimicrob Agents Chemother.2006;50:3875-81.
Newman V,Allwood M, Ökkeş RA. The use of metronidazole gel to control the ameller of malodorous lesions. Pallia Med. 1989;3:303-5.
Nenoff P, Haustein UF, Hittel N. Activity of nadifloxacin (OPC-7251) and seven other antmicrobial Agents against aerobik and anaerobic Gram-positive bacteria isolated from bacterial sakin infections. Chemotherapy. 2004;50:196-201.
An İ, Esen M. Nitrofurazon’a bağlı gelişen alerjik kontak dermatit: Editöre mek- tup. J Anatol Med Res. 2018; 3(1): 33-35.
Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The and- rogen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab. 1993 Feb;76(2):524-8.
Rosen T, Albareda N, Rosenberg N, Alonso FG, Roth S, Zsolt I, et al.Efficacy and safety of ozenoxacin cream for treatment of adult and pediatric patients with impetigo: A randomized clinical trial. JAMA Dermatol 2018;154:806‑13.
Trivedi NR, Gilliland KL, Zhao W, Liu W, Thiboutot DM. Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflam- mation and matrix remodeling. J Invest Dermatol. 2006 May;126(5):1071-9.
Chronnell CM, Ghali LR, Ali RS, Quinn AG, Holland DB, Bull JJ, et al. Human beta defensin-1 and -2 expression in human pilosebaceous units: upregulation in acne vulgaris lesions. J Invest Dermatol. 2001 Nov;117(5):1120-5.
Yang YS, Lim HK, Hong KK, Shin MK, Lee JW, Lee SW, et al. Cigarette smoke-in- duced interleukin-1 alpha may be involved in the pathogenesis of adult acne. Ann Dermatol. 2014 Feb;26(1):11-6.
Snast I, Dalal A, Twig G, Astman N, Kedem R, Levin D, et al. Acne and obe- sity: A nationwide study of 600,404 adolescents. J Am Acad Dermatol. 2019 Sep;81(3):723-9.
Cerman AA, Aktas E, Altunay IK, Arici JE, Tulunay A, Ozturk FY. Dietary glyce- mic factors, insulin resistance, and adiponectin levels in acne vulgaris. J Am Acad Dermatol. 2016 Jul;75(1):155-62.
Chiu A, Chon SY, Kimball AB. The response of skin disease to stress: changes in the severity of acne vulgaris as affected by examination stress. Arch Dermatol. 2003 Jul;139(7):897-900.
Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Con- lon BP, et al. A new antibiotic kills pathogens without dete- ctable resistance. Nature 2015;517:455-9. doi: 10.1038/ nature14098.
Falcone M, Paul M, Yahav D, Orlando G, Tiseo G, Prendki V, et al. Antimicrobial con- sumption and impact of antimicrobial stewardship programmes in long- term care facilities. Clin Microbiol Infect 2019; 25: 562–9.
Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis. 2005 Apr 1;40(7):997-1004. doi: 10.1086/428125. Epub 2005 Mar 4. PMID: 15824992.
Biedron, C, Chopra, T. Issues Surrounding Antibiotic Use in Older Adults. Curr Transl Geriatr and Exp Gerontol Rep 2, 151–158 (2013). https://doi.org/10.1007/s13670-013-0050-9
High KP. Infections in Older Adults (2020). (P. 3704-3710) In Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. [edited by] John E. Bennett, Raphael Dolin, Martin J. Blaser. Philadelphia, PA : Elsevier/Saunders, Chicago.
Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve:mini- mum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneu- monia. J Infect Dis 2004;189:1590-7.
Ayaz C. Beta laktamların genel özellikleri ve penisilinler. 3. Baskı Enfeksiyon hastalıkları ve mikrobiyolojisi sistemlere göre enfeksiyonlar ed: Topçu AW, Söyletir G, Doğanay M. İstanbul: Nobel Tıp Kitabevi 2008. p. 266-78.
Lesher J,Woody MC.Antimikrobiyal ilaçlar . İn:Bolognia JL, Rapini RP,editörs.Dermatoloji( Çevre:Sarıcaoğlu H, Başkan EB),2nd de.İstanbul:Nobel Tıp Kitabevleri:2012.p.1953-60
Sheldon PA, Silbergleit I. pharmacogeriatrics. Pharmacotherapy 1985;5:314-26.
Lexington MA. Cubicin (daptomycin). Cubist Pharmaceuticals 2003.
Nicolle L. Best pharmacological practice: urinary tract infections. Expert Opin Pharmacother 2003:4;693-704.
Kayaalp O. Makrolid, linkozamid ve streptogramin antibiyotikler ve linezolid. Akılcıl Tedavi Yönünden Tıbbi Farmakoloji. 13. Baskı. Ankara: Pelikan Yayıncılık; 2012. p.217-24.
Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089.
Levison ME. Bacteria and antibacterial drugs: Tetracyclines, Tigecycline. In: Porter RS, Kaplan Jl eds. The Merck Manual. 19th ed.MerckDCo Inc 2011.p.1222-4.
Kayaalp O. Tetrasiklinler. Tıbbi Farmakoloji Cilt 1, 5. Baskı. Ankara: Feryal Matbaacılık; 1989. p.691.
Aydın K. Makrolidler ve Linkozamidler. 2007:21;57-61.
Obonyo CO, Juma EA. Clindamycin plus qui- nine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis. Malar J 2012;11:2.
Sivapalasingam S, Steigbigel NH. Macrolides, Clindamycin, and Ketolides. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 7th ed. Philadel phia: Churchill Livingstone; 2010. p.427-48.
Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002;2:659-66.
Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41: 1859-66.
Radandt JM, Marchbanks CR, Dudley MN. In- teractions of fluoroquinolones with other drugs: mechanisms, variability, clinical signif- icance, and management. Clin Infect Dis 1992;14: 272-84.
Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004;75:242- 7.
Nagel JL, Aranoff DM. Metronidazole. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and Prac- tice of Infectious Diseases. 8th ed. Philadelphia: Elsevier; 2015. p.350-7.
Lau AH, Lam NP, Piscitelli SC, et al. Clinical pharmacokinetics of metronidazole and other nitroimidazole antiinfectives. Clin Pharma- cokinet 1992;23(5):328-64.
